A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer

PARP inhibitors in metastatic breast cancer: Where are we now?

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia